SE436831B - Forfarande for framstellning av lekemedelsformer for oral administrering - Google Patents

Forfarande for framstellning av lekemedelsformer for oral administrering

Info

Publication number: SE436831B
Authority: SE; Sweden
Prior art keywords: liquid; cholesterol; ethoxylated; emulsifiers; process according
Prior art date: 1974-07-04

Application number

SE7507413A

Other languages

English (en)

Swedish (sv)

Other versions

SE7507413L (sv

Inventor

J Franz

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-07-04

Filing date

1975-06-27

Publication date

1985-01-28

1975-06-27 Application filed by Sandoz Ag filed Critical Sandoz Ag

1976-01-05 Publication of SE7507413L publication Critical patent/SE7507413L/

1985-01-28 Publication of SE436831B publication Critical patent/SE436831B/sv

Links

238000002360 preparation method Methods 0.000 title claims description 18
238000000034 method Methods 0.000 title claims description 11
239000007788 liquid Substances 0.000 claims description 42
239000003995 emulsifying agent Substances 0.000 claims description 35
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
239000000546 pharmaceutical excipient Substances 0.000 claims description 14
235000012000 cholesterol Nutrition 0.000 claims description 9
150000001841 cholesterols Chemical class 0.000 claims description 9
229960004704 dihydroergotamine Drugs 0.000 claims description 9
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 9
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 8
239000000969 carrier Substances 0.000 claims description 7
229940124531 pharmaceutical excipient Drugs 0.000 claims description 6
LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 claims description 5
229960004318 dihydroergocristine Drugs 0.000 claims description 5
229960004943 ergotamine Drugs 0.000 claims description 4
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims description 4
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 claims description 4
QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 claims description 3
PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 claims description 3
229960002032 dihydroergocryptine Drugs 0.000 claims description 3
238000004108 freeze drying Methods 0.000 claims description 3
239000002609 medium Substances 0.000 claims description 3
241000221785 Erysiphales Species 0.000 claims description 2
229930013930 alkaloid Natural products 0.000 claims description 2
239000012736 aqueous medium Substances 0.000 claims description 2
SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 claims description 2
229960004290 dihydroergocornine Drugs 0.000 claims description 2
QKMRPKVJXKAXHL-OLNIQZLRSA-N dihydroergonine Chemical compound C([C@H]1[C@]2(O)O3)CCN1C(=O)[C@H](C(C)C)N2C(=O)[C@]3(CC)NC(=O)[C@H]1CN(C)[C@H](CC=2C3=C4C=CC=C3NC=2)[C@@H]4C1 QKMRPKVJXKAXHL-OLNIQZLRSA-N 0.000 claims description 2
238000001694 spray drying Methods 0.000 claims description 2
238000002604 ultrasonography Methods 0.000 claims description 2
239000006185 dispersion Substances 0.000 claims 2
ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 claims 1
ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical class C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 claims 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 39
239000013543 active substance Substances 0.000 description 28
239000000203 mixture Substances 0.000 description 27
239000007787 solid Substances 0.000 description 25
239000012876 carrier material Substances 0.000 description 17
229920001223 polyethylene glycol Polymers 0.000 description 17
-1 Kdihydroergotoxin Natural products 0.000 description 16
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 12
150000005846 sugar alcohols Polymers 0.000 description 11
239000002775 capsule Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
150000001298 alcohols Chemical class 0.000 description 9
239000002202 Polyethylene glycol Substances 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
125000004432 carbon atom Chemical group C* 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
238000010438 heat treatment Methods 0.000 description 5
150000004671 saturated fatty acids Chemical class 0.000 description 5
235000003441 saturated fatty acids Nutrition 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 4
210000000941 bile Anatomy 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
229920000573 polyethylene Polymers 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000000126 substance Substances 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
229940079593 drug Drugs 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
229940068886 polyethylene glycol 300 Drugs 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
238000000527 sonication Methods 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 2
239000013011 aqueous formulation Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
VYQDALBEQRZDPL-UHFFFAOYSA-N (2-hexadecanoyloxy-3-hydroxypropyl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCC VYQDALBEQRZDPL-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241000218657 Picea Species 0.000 description 1
QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical class [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229960000807 dihydroergotamine mesylate Drugs 0.000 description 1
ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000007046 ethoxylation reaction Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000010408 film Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000003595 mist Substances 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
LQAVWYMTUMSFBE-UHFFFAOYSA-N pent-4-en-1-ol Chemical group OCCCC=C LQAVWYMTUMSFBE-UHFFFAOYSA-N 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
229940057847 polyethylene glycol 600 Drugs 0.000 description 1
229920000223 polyglycerol Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
125000005624 silicic acid group Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SE7507413A 1974-07-04 1975-06-27 Forfarande for framstellning av lekemedelsformer for oral administrering SE436831B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH920474		1974-07-04

Publications (2)

Publication Number	Publication Date
SE7507413L SE7507413L (sv)	1976-01-05
SE436831B true SE436831B (sv)	1985-01-28

Family

ID=4349465

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE7507413A SE436831B (sv)	1974-07-04	1975-06-27	Forfarande for framstellning av lekemedelsformer for oral administrering

Country Status (18)

Country	Link
JP (1)	JPS5132722A (de)
AT (1)	AT359196B (de)
AU (1)	AU507674B2 (de)
BE (1)	BE831041A (de)
CA (1)	CA1057196A (de)
DE (1)	DE2528257C2 (de)
ES (1)	ES439074A1 (de)
FR (1)	FR2276833A1 (de)
GB (1)	GB1513383A (de)
HK (1)	HK17281A (de)
HU (1)	HU172531B (de)
IE (1)	IE41573B1 (de)
IL (1)	IL47623A (de)
MY (1)	MY8100372A (de)
NL (1)	NL7507745A (de)
PH (1)	PH13763A (de)
SE (1)	SE436831B (de)
ZA (1)	ZA754303B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1090703B (it) *	1976-12-03	1985-06-26	Scherer Ltd R P	Perfezionamento nelle composizioni utili quali veicolo per farmaci
DE2707878C2 (de) *	1977-02-24	1986-01-30	Kali-Chemie Pharma Gmbh, 3000 Hannover	Verwendung von Mono- und/oder Diglyceriden mittelkettiger Fettsäuren
SE442265B (sv) *	1978-12-21	1985-12-16	Sandoz Ag	Fast, enteral-overdragen komposition i enhetsform for oral tillforsel innehallande en ergotalkaloid
JPS56104813A (en) *	1980-01-25	1981-08-20	Takeda Chem Ind Ltd	Composition for rectal infusion containing compound having beta-lactam ring
AU543727B2 (en)	1980-06-02	1985-05-02	Ayerst Mckenna & Harrison Inc.	Injectable composition of rapamycin
US4366145A (en) *	1981-06-24	1982-12-28	Sandoz, Inc.	Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation
DE3829643A1 (de) *	1988-09-01	1990-03-15	Roecar Holdings Nv	Phyto- und zoosterole und deren derivate mit verbesserter wasserloeslichkeit

1975
- 1975-06-25 DE DE2528257A patent/DE2528257C2/de not_active Expired
- 1975-06-27 SE SE7507413A patent/SE436831B/sv not_active IP Right Cessation
- 1975-06-30 NL NL7507745A patent/NL7507745A/xx not_active Application Discontinuation
- 1975-06-30 GB GB27470/75A patent/GB1513383A/en not_active Expired
- 1975-07-02 IL IL47623A patent/IL47623A/xx unknown
- 1975-07-02 HU HU75SA00002815A patent/HU172531B/hu not_active IP Right Cessation
- 1975-07-02 PH PH17338A patent/PH13763A/en unknown
- 1975-07-02 IE IE1468/75A patent/IE41573B1/en unknown
- 1975-07-02 ES ES439074A patent/ES439074A1/es not_active Expired
- 1975-07-03 AT AT510975A patent/AT359196B/de not_active IP Right Cessation
- 1975-07-03 CA CA230,702A patent/CA1057196A/en not_active Expired
- 1975-07-03 AU AU82736/75A patent/AU507674B2/en not_active Expired
- 1975-07-03 JP JP50081486A patent/JPS5132722A/ja active Pending
- 1975-07-03 FR FR7520947A patent/FR2276833A1/fr active Granted
- 1975-07-04 ZA ZA754303A patent/ZA754303B/xx unknown
- 1975-07-04 BE BE158021A patent/BE831041A/xx not_active IP Right Cessation
1981
- 1981-04-30 HK HK172/81A patent/HK17281A/xx unknown
- 1981-12-30 MY MY372/81A patent/MY8100372A/xx unknown

Also Published As

Publication number	Publication date
FR2276833B1 (de)	1978-11-10
ATA510975A (de)	1980-03-15
SE7507413L (sv)	1976-01-05
IL47623A (en)	1979-05-31
JPS5132722A (de)	1976-03-19
IL47623A0 (en)	1975-10-15
DE2528257C2 (de)	1986-02-13
AU8273675A (en)	1977-01-06
ZA754303B (en)	1977-02-23
HK17281A (en)	1981-05-08
IE41573B1 (en)	1980-01-30
HU172531B (hu)	1978-09-28
AU507674B2 (en)	1980-02-21
AT359196B (de)	1980-10-27
ES439074A1 (es)	1977-05-16
GB1513383A (en)	1978-06-07
CA1057196A (en)	1979-06-26
IE41573L (en)	1976-01-04
DE2528257A1 (de)	1976-01-22
MY8100372A (en)	1981-12-31
BE831041A (fr)	1976-01-05
PH13763A (en)	1980-09-18
NL7507745A (nl)	1976-01-06
FR2276833A1 (fr)	1976-01-30

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 7507413-8

Effective date: 19920109

Format of ref document f/p: F

Publication	Publication Date	Title
DE69837903T2 (de)	2008-02-14	Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
EP1487416B1 (de)	2009-12-02	Arzneimittel-mikroteilchen
TWI428125B (zh)	2014-03-01	對包括vx-950之藥物實施噴霧乾燥之方法及由此方法製備之產物
DE69823663T2 (de)	2005-05-19	Selbstemulgierbare formulierung enthaltend lipophile verbindungen
ES2240222T3 (es)	2005-10-16	Procedimiento para producir particulas nanometricas mediante secado por pulverizacion en lecho fluidizado.
DE69624564T2 (de)	2003-03-20	Misoprostolhaltige feste stabilisierte dispersionen
EP0326618A1 (de)	1989-08-09	Medizinische zusammensetzung, welche albumin als träger enthält, und verfahren zu deren herstellung
EP0702562A1 (de)	1996-03-27	Cyclosporin-enthaltene puderzusammensetzung
JP2001505928A (ja)	2001-05-08	シクロスポリン及び陰イオン性界面活性剤を含む固体医薬組成物
HRP20020111A2 (en)	2003-04-30	Pharmaceutical composition containing fenofibrate and preparation method
HUP0100412A2 (hu)	2001-12-28	Aritmia ellen hatásos benzofuránszármazékot tartalmazó javított biohasznosulású szilárd gyógyszerkészítmény
EP1741424B1 (de)	2018-10-03	Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
JP2007501218A (ja)	2007-01-25	非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
KR100367302B1 (ko)	2003-04-16	소수성활성물질과발포제를포함하는제약학적조성물과이의준비공정
DE69129918T2 (de)	1999-02-04	Ein in Wasser schwerlösliches Arzneimittel enthaltende pharmazeutische Zubereitung
DE602004006000T2 (de)	2008-01-17	Verringerung der teilchengrösse von bioaktiven verbindungen
EP3854384A1 (de)	2021-07-28	Pharmazeutische formulierung, die abirateronacetat umfasst
DE2528257C2 (de)	1986-02-13	Neue galenische Zubereitung
DK169566B1 (da)	1994-12-05	Flydende farmaceutisk præparat indeholdende en 4-aroyl-imidazol-2-on til anvendelse i doseringsformer til oral indgivelse samt fremgangsmåde til fremstilling af præparatet
CN105722392A (zh)	2016-06-29	非核苷逆转录酶抑制剂的组合物
JPS6218527B2 (de)	1987-04-23
JPS6348228A (ja)	1988-02-29	難溶性薬物の易吸収性固形製剤
HU200689B (en)	1990-08-28	Process for producing endermic pharmaceutical compositions comprising pyrazolo(1,5-a)pyridine derivatives as active ingredient
WO2002072100A2 (en)	2002-09-19	Pharmaceutical composition containing pde v inhibitors and surfactants
KR19990075252A (ko)	1999-10-15	비가역성 hiv프로테아제 억제제를 포함하는 경구투여용 약학적 조성물